FMT plus anti-PD-1 in refractory GI cancer, Beijing
56 fecal/blood samples from adult gastric and colorectal cancer patients in Beijing, China, in a phase I single-arm trial of fecal microbiota transplantation combined with anti-PD-1 drug therapy for ICI-refractory disease. machine-written summary
56 samples · 56 runs · CN · Age unknown · 2024 · 12.58 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 574 sample values (collection date, country, health condition, health condition detail, intervention, intervention detail, latitude, location locality) |
| ○ Abstract / description | read; no usable statement |
| ○ Full text | read; no usable statement or table · PMC13034380 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
10 people have samples in more than one arm.
Non-antibiotic pharmaceutical given as the study intervention (metformin Faecal microbiota transplantation design single_arm_before_after · population colorectal_cancer · FMT capsules from healthy donors combined with nivolumab (anti-PD-1)
“fecal microbiota transplantation (FMT) from healthy donors in 10 patients with advanced” — abstract:41871875 (study level; per-sample arms are in the intervention column below)
longitudinalFMT donor → recipient
14 of 15 people sampled more than once (55 samples; median 4, up to 9 per person) · follow-up median 3 mo (max 6 mo) · median interval between samples 22 d (time from collection dates). Schedule stated by the source: “Stool at baseline, weekly Weeks1-3, every other week Weeks4-12, end of study, and study extension phase”.
Each row is one person (10 shown of 14); dots are samples at days since that person's first sample.
10 GI-cancer FMT recipients linked to 5 sequenced capsule donors via capsuleID.
donorrecipient · circles are people (pale = no sequenced sample), arrows run donor → recipient and parent → child, curved lines join twins, partners and siblings, squares are shared settings or families without recorded roles. Shown: 5 linked groups from explicit relations. 15 people in the project overall.
Genera, mean relative abundance over 49 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 56 | 100% | ||||
| country | 56 | 100% | 56 | |||
| health_condition | 42 | 75% | 42 | |||
| subject_id | 56 | 100% | 56 | |||
| detailed_location | 56 | 100% | ||||
| intervention | 56 | 100% | 56 | |||
| intervention_detail | 56 | 100% | 56 | |||
| latitude | 56 | 100% | 56 | |||
| location_locality | 56 | 100% | 56 | |||
| longitude | 56 | 100% | 56 | |||
| timepoint_label | 56 | 100% | 56 | |||
| collection_date | 42 | 75% | 42 | |||
| health_condition_detail | 42 | 75% | 42 |
- Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study. 2026 PMID 41871875 PMC13034380 own_data
Archive description
The discovery and therapeutic application of immune checkpoint inhibitors (ICI) has significantly improved clinical outcomes in cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. Considering the paramount role of gut microbiome in immune modulation, we performed fecal microbiota transplantation (FMT) from healthy donors in 10 GI cancer patients resistant to anti-PD-(L)1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated with no serious adverse reactions observed, and 2 patients restored clinical responsiveness to anti-PD1. Clinical benefits were associated with colonization of donor-derived immunogenic microbes, and an activated immune status reflected by peripheral immune cell populations. Moreover, microbial signatures were identified for ICI responsiveness and validated in an independent cohort and in mouse model. The current study demonstrates the feasibility of FMT for ICI-refractory GI cancer patients and provides a foundation for LBP development to enhance ICI efficacy.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.75. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- host study.description · “10 GI cancer patients resistant to anti-PD-(L)1 treatment”
- body site study.title · “Fecal microbiota transplantation”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN39476653 | collection_date | 2019-12-31 | R1 | 0.90 | biosample.attribute:collection_date | 2019-12-31 |
| SAMN39476653 | country | CN | R1 | 0.90 | sample.attr.geo_loc_name | China:Beijing |
| SAMN39476653 | health_condition | colorectal_cancer | R1 | 0.90 | biosample_attr | CRC |
| SAMN39476653 | health_condition_detail | CRC | R1 | 0.90 | sample.attr.host_disease | CRC |
| SAMN39476653 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:Phase | Phase: Before treatment |
| SAMN39476653 | intervention_detail | before FMT treatment | R1 | 0.90 | biosample.attribute:Phase | Phase: Before treatment |
| SAMN39476653 | latitude | 39.0000 | R1 | 0.90 | biosample.attribute:lat_lon | 39 N 116 E |
| SAMN39476653 | location_locality | Beijing | R1 | 0.85 | biosample.attribute:geo_loc_name | China:Beijing |
| SAMN39476653 | longitude | 116.0000 | R1 | 0.90 | biosample.attribute:lat_lon | 39 N 116 E |
| SAMN39476653 | subject_id | LH001 | R1 | 0.70 | sample.name_rule:alias | LH001-1 |
| SAMN39476653 | timepoint_label | Before treatment | R1 | 0.85 | sample.attr.phase | Before treatment |
Sequencing
56 runs over 56 samples · mean 14.08 Gbp per run (median 12.58 Gbp, total 788.47 Gbp; 56 runs with a base count) · layout PAIRED 56 · platform ILLUMINA 56 · models Illumina NovaSeq 6000 (56) · 88% of runs with a Sandpiper profile · first public 2024-01-19
Authors (25)
Zhang Y first · Xu X · Wang S · Yin X · Zhang B · Zhu Z · Ji R · Zhu J · He H · Cheng S · Han Z · Xie T · Zhang X · Wang Y · Shen S · Kou Y · Bao S · Liu Y · Cao B · Bonny C · Guo X · Segal E · Tan Y · Shen L · Peng Z last
Downloads
PRJNA1065951.csv.gz (2.7 KB) · parquet (73.1 KB) — all 56 samples, every field with route and confidence · PRJNA1065951_determinations.csv.gz (4.7 KB) — 574 evidence rows